Talon Therapeutics Inc (fka TLON)

[bmatt]

What concerns me is the sentence in the section:"Rights to Purchase Series A-3 Preferred Stock": 10-Q March 31

"As a result of the Company's receipt of approval from the FDA to market Marqibo on August 9, 2012, the Purchaser's right to purchase additional shares of Series A-3 Preferred expires on August 9, 2013."

This places a hard stop for any additional infusion of capital from WP via a purchase of Series A-3 shares on August 9th, which is only a few weeks away.

So, they either amend that agreement, partner or sell the company. I guess they could also go out for out-side funding.